KM Research Hub
← 返回结果库查看论文详情PubMed ↗
READ-ONLY DIGITIZATION RESULT

Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial.

Circulation · 2025-Jun-10 · PMID 40156843

Panel E质量警告待 EXE 对齐验证

Time to all-cause death

Figure 1. Cumulative incidence plots of outcomes for oral semaglutide vs placebo in subgroups with or without SGLT2i use at baseline. A , Time to first occurrence of MACE. B , Time to cardiovascular death. C , Time to first nonfatal myocardial infarction event. D , Time to first nonfatal stroke event. E , Time to all-cause death. The cumulative incidence rate is calculated using the Aalen-Johansen method with noncardiovascular death ( A and B )/all-cause death ( C and D ) as a competing risk. CV indicates cardiovascular; HR, hazard ratio; MACE, major adverse cardiovascular event; MI, myocardial infarction; and SGLT2i, sodium-glucose cotransporter-2 inhibitor

算法:legacy-0.5.0引擎:enhanced-linux
质量评分0.34
质量通过否
预期曲线4
实际曲线1
X 范围-
Y 范围-

曲线数据

网页最多预览 200 行,完整数据请下载 CSV 或 JSON。

当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)

重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。

版本状态验证曲线时间
legacy-0.5.0quality_warning待验证12026-07-23T18:08:52+00:00